Trident Lifeline Ltd. · BSE:TLL
Trident Lifeline — Q3 FY2023 Earnings Presentation
29 slides from Trident Lifeline's earnings presentation, Jan 20, 2023
Slide 1: KUNAL AMRISHBHAI CHAUHAN
KUNAL Digitally signed by KUNAL AMRISHBHAI CHAUHAN DN: c=IN, o=PERSONAL, title=0993, pseudonym=40f85186b1cf404784e07c4c0b9e139e, 2.5.4.20=cc5739849ebcc5622b1ed0c8b692d10e79e24 AMRISHBHAI de2a05e7a160d5158d74777925d, postalCode=380050, st=Gujarat, serialNumber=2be72bb51d3cdb982bdbfb6047e898c1 CHAUHAN
Slide 2: Q3FY23 Presentation
Q3FY23 Presentation Tr i d e n t L i f e l i n e L i m i t e d January 2023
Slide 3: Inside the document
Inside the document Pg. 03 __ Company Over view Pg. 08 __ Expansive Product Portfolio Pg. 12 __ Global Footprint Pg. 17 __ Leadership Pg. 19 __ Strategy & Investment Rationale Pg. 22 __ Financials & Management Commentar y
Slide 4: Company Overview
| i 9 Company || Overview
Slide 5: Trident Texofab Group
Trident Texofab Group Part of the Trident Texofab Group (“the Group”) with interests in textiles, pharmaceuticals and medical equipments. Trident Texofab Trident Lifeline Trident Mediquip Limited Limited Limited Trident Texofab Limited, a semi-composite Trident Lifeline Limited is a diversified Trid
Slide 6: Introduction to Trident Lifeline
Introduction to Trident Lifeline About us A growing force in pharmaceutical Trident Lifeline Limited (“Trident formulations export. Vision Lifeline” or “the Company”) 341 746 15 To be a leading is a diversified pharmaceutical pharmaceutical company Company with business globally by providing high- q
Slide 7: Superior Business Model
Superior Business Model A growing force in 341 746 15 pharmaceutical Export market Export market product Countries present formulations products registered registrations in process in globally export Asset-light third-party Asset-light State-of-art contract Contract manufacturing model, State-of-art
Slide 8: Presence across Value Chain
Presence across Value Chain Procurement Manufacturing Exports Sales & Marketing Complete control over supply- • Third-party contract • Engaged in direct exports • Dedicated sales & marketing chain, procurement done by manufacturing under own brands & product team for branded sales Trident Lifeline i
Slide 9: Expansive Product Portfolio
Expansive Product Portfolio
Slide 10: Expansive Product Portfolio
Expansive Product Portfolio The Company’s growing portfolio of products spans over Product categories ▸ Anti Bacterial ▸ Anti Diarrheal ▸ Anti Fungal ▸ Anti Malarial ▸ Anti Diabetic ▸ Dental Cure ▸ Proton Pump Inhibitor ▸ Anti Protozoal Product Categories ▸Anti Histamine 12 ▸Anti Hypertensive drugs
Slide 11: Expansive Product Portfolio (continued)
Expansive Product Portfolio (continued) The Company’s growing portfolio of products spans over Product categories ▸ Capsule ▸ Tablet ▸ Liquid Ointment ▸ Gel ▸ Ice Gel ▸ Mouthwash Product Categories ▸ Paste 12 ▸ Solution ▸ Suspension ▸ Toothpaste Therapeutic Categories 16 ▸ Syrup ▸ Cream 2 PRODUCT PO
Slide 12: Revenue Break-up: Product Categories
Expansive Product Portfolio (continued) Revenue Break-up: Product Categories Tablets are by far the largest product category (In %) accounting for~52% of the revenue 51.9 51.4 Followed by capsules being the second largest category which accounts for ~31% of the revenue. 41.2 30.7 Other categories in
Slide 13: Growing Global Footprint
Growing Global Footprint
Slide 14: Growing Geographical Footprint
Growing Geographical Footprint Trident Lifeline has a growing geographical footprint and a formidable presence export markets such as African, Latin American, CIS and East Asian Uzbekistan countries. Tajikistan 8 Venezuela Sudan India Myanmar Cambodia Countries where products are registered Ghana Ni
Slide 15: Geographical Revenue Mix
Geographical Revenue Mix Being an export-oriented The share of exports Ghana is a major export market for the Other major markets include Company, Trident has been have increased from country and has accounted for a India, Venezuela & constantly increasing the 55% in FY20 to 85% significant share ov
Slide 16: Bolstering Export Growth
Bolstering Export Growth Trident Lifeline has been making Export product registrations are consistent, upfront investments in a painstaking task, involving export product registrations to significant gestation period bolster revenue growth of 1.5 to 3 years. The Company also needs to register Till d
Slide 17: Bolstering Export Growth (continued)
Bolstering Export Growth (continued) Country-wise product bifurcation Cambodia, Ghana, Kenya, Venezuela (In %) & Nigeria combined accounts for Ghana 297 75% the total product registered and Cambodia 168 under registration. Kenya 146 Venezuela 120 Nigeria 79 Ghana has total 297 products registered &
Slide 18: Leadership
Q ‘c LY Yo O xe) O O —I
Slide 19: Board of Directors
Board of Directors Mr. Hardik Jigishkumar Desai Mr. Shravan Harikrishna Patel Mr. Mayurkumar Mansukhbhai Gajera Mr. Hardik Jigishkumar aged 44 years is Mr. Shravan Harikrishna Patel aged 28 Mr. Mayurkumar Mansukhbhai Gajera aged 37 Promoter-Chairman and Executive Director years is Managing Director
Slide 20: Strategy & Investment Rationale
Strategy & Investment Rationale
Slide 21: Strategic Priorities
Strategic Priorities Continuous Expanding investments in intellectual Building sales & Strengthening Expand product product property marketing supply chain portfolio registrations registrations prowess • 300-400 additional • Registering brand’s • Strengthening strategic • Expanding dedicated • Grow
Slide 22: Investment Rationale
Investment Rationale • Trident’s business model reaps • 746 registrations in pipeline spread backloaded investment Extensive over 15 countries, with many benefits of product Exponential registrations under process registrations product growth registrations • Post registrations, potential to grow • C
Slide 23: Financials & Management Commentary
Financials & Management Commentary
Slide 24: Quarterly Profit & Loss Snapshot
Quarterly Profit & Loss Snapshot (₹ in Lakh) Particulars Q3FY23 Q2FY23 Q3FY22 YOY Change (%) +118% YOY Revenue growth in Q3FY23 Total Revenue 980.18 797.28 449.17 118% Total Operating Expenses 742.93 626.42 503.55 48% EBITDA 237.25 170.86 -54.38 536% EBITDA (%) 24% 21% -12% +3,631 BPS +536% YOY EBIT
Slide 25: Annual Profit & Loss Snapshot
Annual Profit & Loss Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 9MFY23 Total Revenue 505.63 978.12 2,237.14 2,375.51 Total Operating Expenses 517.2 836.93 1,905.95 1,893.34 EBITDA -11.57 141.2 331.2 482.17 EBITDA (%) -2% 14% 15% 20% Interest Cost 76.21 41.23 12.58 31.18 Depreciation & Amortisat
Slide 26: Management Commentary
Management Commentary • Trident Lifeline continues to report robust financial performance with growth across all key parameters. On the topline front, the Company reported its highest-ever quarterly topline at ₹ 980.18 Lakhs, a substantial growth on both YoY and QoQ basis. In 9MFY23 the Company repo
Slide 27: Balance Sheet Snapshot
Balance Sheet Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 Shareholders Fund -500.31 -217.21 477.57 Non Current Liability 646.93 457.65 148.94 Current Liability 103.24 333.81 186.82 Trade Payable 183.41 401.80 569.16 Total 433.27 976.05 1382.49 Non Current Assets 161.42 143.57 318.64 Current Asse
Slide 28: Cash Flow Snapshot
Cash Flow Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 Cash from Operating Activities -81.86 -32.02 -19.19 Cash from Investing Activities -13.63 24.79 -49.52 Cash from Financing Activities 103.75 1.43 80.19 Net Cash Flow 8.26 -5.80 11.48 Net Cash at Beginning of Year 4.12 12.38 1.46 Net Cash at t
Slide 29: Safe Harbour
Safe No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of